1. Introduction {#sec1}
===============

Chemotherapy, a major cancer treatment, is aimed at ameliorating symptoms and prolonging patients\' life \[[@B1]\]. However, nausea and vomiting are common side effects of chemotherapy in patients with cancer; these effects are defined as chemotherapy-induced nausea and vomiting (CINV) \[[@B2], [@B3]\]. Neurotransmitters, such as 5-hydroxytryptamine, substance P, and dopamine, may play an important role in CINV. Treatment- and patient-specific effects are risk factors for CINV \[[@B4], [@B5]\].

Based on the emetogenic potential of intravenous antineoplastic agents, chemotherapeutic drugs can be classified into four categories: high-emetic-risk (higher than 90%), moderate-emetic-risk (30%--90%), low-emetic-risk (10%--30%), and minimal-emetic-risk (lower than 10%) agents \[[@B1], [@B6]\]. Considering the duration of nausea and vomiting, CINV can be classified into the following categories: acute CINV, which occurs in a few minutes of chemotherapy and can be relieved in 24 hours; delayed CINV, which occurs after more than 24 hours, typically reaches its peak from 48 to 72 hours, and can last 5 days after chemotherapy; and anticipatory emesis, which may occur when patients see or smell the chemotherapeutic drugs \[[@B1], [@B6]\]. Many agents are available for preventing CINV, and they include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Dopamine receptor antagonists, benzodiazepines, olanzapine, and cannabinoids are other alternatives \[[@B1], [@B2], [@B6]--[@B9]\].

CINV occurs in 70--80% patients treated with chemotherapy \[[@B2], [@B3]\]. Although antiemetic drugs can ameliorate symptoms to a certain extent, they result in other side effects such as diarrhea, fatigue, headache, and transaminase elevation \[[@B6]\]. However, approximately 30%--60% of patients experience nausea and vomiting despite using antiemetic drugs \[[@B2]\]. CINV can cause anxiety and depression and reduce patients\' quality of life. Furthermore, CINV negatively affects 20% patients\' will to complete the cancer treatment \[[@B2]\]. Occasionally, patients postpone or refuse to continue chemotherapy because of the mentioned reasons \[[@B3], [@B8], [@B10]\]. Therefore, preventing and relieving CINV in patients with cancer have become a major concern in cancer treatment.

Moxibustion, a traditional Chinese medicine treatment, involves the use of burning moxa (dried leaves of an Asian species of mugwort) to generate heat and stimulate acupoints. Direct and indirect moxibustion are the frequently used moxibustion techniques. Direct moxibustion entails igniting a moxa cone or stick directly on acupoints, whereas indirect moxibustion involves using certain types of materials, such as ginger, salt, or herbs, between the ignited moxa cone or stick and acupoints. The treatment is continued until the skin turns red and patients feel warm and comfortable around the acupoints. Moxibustion is a noninvasive, painless, and easily operative treatment with fewer adverse events, and patients can perform it at home. In addition, it is considered a safe and effective complementary treatment \[[@B11], [@B12]\].

Two systematic reviews, published in Chinese and English languages, have analyzed the effects of moxibustion on chemotherapy-related side effects \[[@B12], [@B13]\]. These reviews have reported that moxibustion could facilitate alleviating chemotherapy-induced side effects, particularly nausea and vomiting. Nevertheless, drawing an accurate conclusion from these reviews is difficult because of limited evidence. Recent (2005--2017) randomized controlled trials (RCTs) \[[@B16]--[@B31]\] have investigated CINV, but without further analysis. Therefore, we conducted this systematic review to determine the effectiveness of moxibustion.

2. Methods {#sec2}
==========

2.1. Review Question {#sec2.1}
--------------------

Can moxibustion relieve the severity and frequency of CINV?

2.2. Types of Studies {#sec2.2}
---------------------

We included RCTs on the effects of moxibustion on CINV that were published in Chinese and English. Non-RCTs, quasi-randomized trials, reviews, animal trials, or trials without full texts were excluded. Eligible RCTs included those involving randomized control, diagnostic criteria, intervention measures, and statistical methods. The results matched with the criteria used in each RCT.

2.3. Types of Patients {#sec2.3}
----------------------

Patients diagnosed as having cancer and CINV were included. Differences in age, sex, race, and educational or economic status among patients were disregarded.

Patients with mental disorders, acute infections, and allergy to moxibustion, as well as those with diseases that may cause nausea and vomiting, were excluded.

2.4. Types of Interventions {#sec2.4}
---------------------------

Two types of moxibustion were included: direct and indirect moxibustion. Control interventions included no treatment, antiemetic drugs, and placebo moxibustion.

Comparisons between moxibustion types were excluded. Comparisons of moxibustion with Chinese medicine or acupuncture were also excluded.

2.5. Types of Outcome Measures {#sec2.5}
------------------------------

The primary outcome was the severity and frequency of CINV during chemotherapy. Three criteria were used to evaluate the severity and frequency of nausea and vomiting: the World Health Organization (WHO) criterion for acute and subacute toxicity of anticancer agents, curative effect of Eastern Society for Medical Oncology (ESMO), and score of the European Organization for Research on Treatment of Cancer questionnaire v3.0 (EORTC QLQ-C30 v3.0; the nausea and vomiting domain).

The secondary outcomes were the physical condition and quality of life after chemotherapy. The Karnofsky performance score (KPS) was used to estimate the physical condition, and EORTC QLQ-C30 v3.0 was used to assess quality of life. Adverse events were also evaluated.

2.6. Search Methods for Study Identification {#sec2.6}
--------------------------------------------

We searched the following databases from their inception until February 2017 for RCTs investigating the effects of moxibustion on CINV that have been published in Chinese and English: EMBASE, PubMed, Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Medical Current Content, Chinese Scientific Journal Database (VIP database), and Wanfang Database. Ongoing and registered trials were searched in two trial registries (<https://www.clinicaltrials.gov> and <http://www.who.int/trialsearch/Default.aspx>).

The PubMed database was searched using the search strategy in the Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 \[[@B14]\]. The following keywords were used: (randomized controlled trial OR controlled clinical trial OR randomized OR randomly OR trial OR groups) AND (moxibustion OR moxabustion OR mugwort OR moxa) AND (drug therap^*∗*^ OR chemotherap^*∗*^ OR pharmacotherap^*∗*^) AND (nausea OR vomiting OR emesis). The search strategy for the other online databases was adjusted according to their requirements.

2.7. Selection of Studies {#sec2.7}
-------------------------

The studies selected from the databases were integrated into Endnote X7 (Thomson Reuters, New York, NY, USA). After removing duplicate studies, two authors (Z. H. and Q. Y.) conducted primary screening by reviewing the titles and abstracts of each trial to select eligible trials. They subsequently performed secondary screening by reviewing the full texts of each trial to select eligible trials and further assess them. These steps were separately completed by the two authors. Differences in opinion between the two authors were resolved by a third author (Z. L.).

2.8. Extraction and Management of Data {#sec2.8}
--------------------------------------

The data from each included trial were extracted and recorded in a data extraction form by two authors (Z. H. and Q. Y.) separately. The following factors were analyzed: general information (publication country, year, language, and author details), participants (baseline characteristics, inclusion criteria, exclusion criteria, and sample size), interventions (type, frequency, and course of moxibustion), comparisons (type, dose, frequency, and course of comparison treatments), outcomes (severity and frequency of nausea and vomiting, score of the included scale and questionnaire), and adverse events. The authors of the studies were contacted, when required. RevMan V.5.3 was used for data analysis.

2.9. Assessment of Risk of Bias in Included Studies {#sec2.9}
---------------------------------------------------

The Cochrane Collaboration tool for assessing the risk of bias in randomized trials \[[@B15]\] was used to assess the risk of bias in each included trial. The following evaluations were performed by two authors (Z. Q. and Q. Y.) separately: selection bias (random sequence generation and allocation concealment), performance bias (blinding of the participants and personnel), detection bias (blinding of the outcome assessment), attrition bias (incomplete outcome data), reporting bias, and other sources of bias. We assessed publication bias by using funnel plots; however, this process could not be completed because of the limited number of trials. The third author (Z. L.) made final decisions on this process.

2.10. Data Synthesis {#sec2.10}
--------------------

We used RevMan V.5.3 for data synthesis. A meta-analysis was performed to analyze the study data, if possible. We used the risk ratio (RR) and mean difference (MD) to explain dichotomous and continuous outcomes, respectively. The outcomes were within 95% confidence intervals (CIs).

Considering the differences in each trial (variations in chemotherapy, moxibustion type, acupoints, and antiemetic drugs), the random-effects model was used to perform the meta-analysis.

The *I*^2^ statistic was used for assessing statistical heterogeneity. We classified the articles with *I*^2^ \< 50% as having low heterogeneity, whereas those with *I*^2^ \> 75% were classified as having high heterogeneity. We determined the potential factors for heterogeneity by performing a sensitivity analysis. Instead of a meta-analysis, a descriptive analysis was performed when *I*^2^ \> 75%.

3. Results {#sec3}
==========

3.1. Results of the Search {#sec3.1}
--------------------------

We obtained 272 studies from the online databases; we included 251 studies after removing duplicates. Through primary screening, we ruled out 190 studies by screening their titles and abstract. After reviewing the full texts of 61 studies, we excluded studies because they were not true RCTs (*n* = 4), were duplicates (*n* = 6), lacked adequate data (*n* = 30), conducted comparisons with other traditional Chinese medicine treatments (*n* = 2), were case reports (*n* = 1), and had no full text (*n* = 2). Finally, 16 trials matched our study criteria and were included in this systematic review and meta-analysis \[[@B16]--[@B31]\]. These trials were published in Chinese during September 2005 and February 2017. One trial \[[@B30]\] was conducted in Mongolia, whereas others have been conducted in China. Two trials \[[@B20], [@B28]\] were determined to be multicenter trials, whereas the rest were determined to be single-center trials.

[Figure 1](#fig1){ref-type="fig"} summarizes the progress of study selection.

3.2. Patients {#sec3.2}
-------------

We included a small sample of 1123 patients (age: 20--80 years) from the 16 trials in our systematic review. Patients in all trials were diagnosed as having cancer and received chemotherapy. Patients were diagnosed as having lung cancer in three trials (*n* = 170) \[[@B21], [@B26], [@B31]\], breast cancer in one trial (*n* = 58) \[[@B25]\], colon cancer in one trial (*n* = 60) \[[@B23]\], and gastric cancer in one trial (*n* = 91) \[[@B20]\]. The remaining patients (*n* = 744) were diagnosed as having various other cancers (esophageal cancer, ovarian cancer, liver cancer, and nasopharyngeal cancer).

3.3. Interventions of Moxibustion {#sec3.3}
---------------------------------

Practitioners typically select acupoints for moxibustion based on traditional Chinese medicine theories and clinical experience. Ten trials used direct moxibustion: wheat moxibustion (*n* = 1) \[[@B16]\], moxa box moxibustion (*n* = 1) \[[@B29]\], cone moxibustion (*n* = 1) \[[@B19], [@B21], [@B26], [@B30], [@B32]\], and stick moxibustion (*n* = 3) \[[@B17], [@B22], [@B23]\]. The remaining six trials used indirect moxibustion: ginger-partitioned moxibustion (*n* = 5) \[[@B18], [@B24], [@B25], [@B27], [@B28]\] and herb-partitioned moxibustion (*n* = 1) \[[@B20]\]. Zusanli (ST36; 10/16, 62.50%), Zhongwan (RN12; 6/16, 37.50%), Geshu (BL17; 5/16, 31.25%), and Danshu (BL19; 4/16, 25.00%) were the frequently used acupoints. Moxibustion was performed before the chemotherapy course in three trials \[[@B23], [@B24], [@B28]\], whereas in the remaining trials, it was conducted during the chemotherapy course. Moxibustion was typically operated until the patients\' local skin became warm and turned red. Moxibustion was conducted once daily (*n* = 12), twice daily (*n* = 2), three times weekly (*n* = 1), and six times weekly (*n* = 1).

3.4. Control Interventions {#sec3.4}
--------------------------

Five trials compared moxibustion with antiemetic drugs \[[@B16], [@B19], [@B20], [@B23], [@B25]\], and seven compared moxibustion plus antiemetic drugs with the same antiemetic drugs \[[@B17], [@B18], [@B22], [@B26], [@B29]--[@B31]\]. The antiemetic drugs used in these 12 trials belong to the 5-HT3 receptor antagonist family. Three trials compared moxibustion with no treatment \[[@B21], [@B27], [@B28]\]. One trial compared actual moxibustion with placebo moxibustion (a thick paper between the moxa and acupoints) on the same acupoints \[[@B24]\]. One trial \[[@B20]\] did not mention the control intervention in the English abstract, the details of control group can be found in the full text. Three trials \[[@B23], [@B25], [@B26]\] did not have English abstract, the details of intervention and control intervention can be found in the full text.

3.5. Outcome Measures {#sec3.5}
---------------------

The primary outcome was the severity and frequency of CINV in complete response during the chemotherapy course. Based on the American Society of Clinical Oncology (ASCO) guidelines and relevant studies \[[@B1], [@B32], [@B33]\], complete response was described as no nausea or vomiting and no use of emergency antiemetic drugs after chemotherapy; complete response matched grade 0 of the WHO and ESMO criteria. Three trials \[[@B25], [@B27], [@B30]\] reported the scores in the nausea and vomiting domain of EORTC QLQ-C30 v3.0, whereas the remaining studies reported the grade of nausea and vomiting according to the WHO or ESMO criterion. All outcomes of the included trials were assessed during the chemotherapy course.

[Table 1](#tab1){ref-type="table"} summarizes the characteristics of each trial.

3.6. Risk of Bias {#sec3.6}
-----------------

Randomization was conducted in all 16 RCTs. Nine trials used a table of random numbers \[[@B16]--[@B18], [@B20], [@B24], [@B25], [@B27], [@B28], [@B31]\], and one used JMTJFX software to generate random numbers \[[@B21]\]. Details on the randomization methods of six trials could not be obtained despite contacting the authors. Only three trials reported allocation concealment \[[@B24], [@B25], [@B27]\]. However, these three trials were considered as having an unclear risk of selection bias because of the lack of an indication of whether the envelope was sealed and opaque. Two trials were considered as having a high risk of reporting bias; one study \[[@B25]\] lacked final KPSs after chemotherapy and the other \[[@B28]\] lacked data on supportive treatment and emergency antiemetic drug use. Only one trial \[[@B24]\] used a patient-blinded method, whereas others did not, because of the characteristics of moxibustion. Three trials \[[@B16], [@B17], [@B25]\] reported 11 dropouts, and only one of them \[[@B17]\] provided details on their dropouts. Three trials \[[@B22], [@B24], [@B29]\] were considered as having an unclear risk of other sources of bias because of the lack of data on consistent baseline characteristics.

[Table 2](#tab2){ref-type="table"} summarizes the risk of bias in the included studies.

3.7. Effects of Moxibustion versus No Treatment {#sec3.7}
-----------------------------------------------

### 3.7.1. Primary Outcomes {#sec3.7.1}

Nausea and vomiting were assessed using WHO criterion. Two trials (*n* = 120) \[[@B21], [@B28]\] reported that moxibustion might more effectively relieve the severity of CINV, compared with no treatment (RR: 2.04, 95% CI: 1.42--2.93, *n* = 120, and *I*^2^ = 0%, low-quality evidence; [Figure 2](#fig2){ref-type="fig"}).

*Nausea and Vomiting Assessed Using EORTC QLQ-C30 v3.0.* One trial \[[@B27]\] revealed that moxibustion might effectively relieve the severity of CINV, compared with no treatment (23.73 ± 19.93 versus 37.73 ± 25.19).

### 3.7.2. Secondary Outcomes {#sec3.7.2}

Physical condition assessed using the KPS. A combination of three trials \[[@B21], [@B27], [@B28]\] revealed statistical heterogeneity (MD: 7.83, 95% CI: 2.85--12.81, *n* = 180, and *I*^2^ = 58%, low-quality evidence; [Figure 3](#fig3){ref-type="fig"}). After the trial by Zhong \[[@B28]\] was removed, the heterogeneity decreased to 0% ([Figure 4](#fig4){ref-type="fig"}). The three trials revealed that, compared with no treatment, moxibustion may improve the physical condition of patients.

### 3.7.3. Adverse Events {#sec3.7.3}

Two trials \[[@B21], [@B27]\] reported no adverse events in the intervention or control group.

3.8. Effects of Moxibustion versus Antiemetic Drugs {#sec3.8}
---------------------------------------------------

### 3.8.1. Primary Outcomes {#sec3.8.1}

Nausea and vomiting were assessed using the WHO criterion. Four trials \[[@B19], [@B20], [@B23], [@B25]\] revealed that moxibustion may more favorably relieve the severity of CINV, compared with antiemetic drugs (RR: 1.54, 95% CI: 1.25--1.88, *n* = 270, and *I*^2^ = 5%, low-quality evidence; [Figure 5](#fig5){ref-type="fig"}).

*Nausea and Vomiting Assessed Using the ESMO Criterion.* One trial \[[@B16]\] that measured outcomes using the ESMO criterion 1996 reported that moxibustion may have more favorable effects on relieve the severity and frequency of CINV than antiemetic drugs (19/27 versus 9/29).

### 3.8.2. Secondary Outcomes {#sec3.8.2}

Physical condition assessed using the KPS. Two trials \[[@B16], [@B19]\] revealed that moxibustion may more effectively improve the physical condition of patients than antiemetic drugs (MD: 10.63, 95% CI: 7.80--13.46, *n* = 118, and *I*^2^ = 0%, low-quality evidence; [Figure 6](#fig6){ref-type="fig"}).

### 3.8.3. Adverse Events {#sec3.8.3}

Trials in this group did not report any adverse events in the intervention or control group.

3.9. Effects of Moxibustion Plus Antiemetic Drugs versus Antiemetic Drugs Alone {#sec3.9}
-------------------------------------------------------------------------------

### 3.9.1. Primary Outcomes {#sec3.9.1}

Nausea and vomiting were assessed using the WHO criterion. Three trials \[[@B18], [@B26], [@B31]\] revealed that moxibustion might enhance the effects of antiemetic drugs as a complementary treatment (RR: 2.57, 95% CI: 1.77--3.75, *n* = 178, and *I*^2^ = 0%, low-quality evidence; [Figure 7](#fig7){ref-type="fig"}).

*Nausea and Vomiting Assessed Using the ESMO Criterion.* Two trials measured using the EMSO criterion 1990 \[[@B22], [@B29]\] with statistical heterogeneity revealed that moxibustion could not enhance the effects of antiemetic drugs as a complementary treatment (MD: 1.49, 95% CI: 0.92--2.43, *n* = 249, and *I*^2^ = 79%, low-quality evidence; [Figure 8](#fig8){ref-type="fig"}). One trial measured using the ESMO criterion 1996 \[[@B17]\] reported that moxibustion may enhance the effects of antiemetic drugs as a complementary treatment (complete response; 5/31 versus 2/30).

*Nausea and Vomiting Assessed Using EORTC QLQ-C30 v3.0.* One trial \[[@B30]\] reported that moxibustion may enhance the effects of antiemetic drugs as a complementary treatment and yield an increased score in the nausea and vomiting domain (complete response; 24.5 ± 30.0 versus 36.3 ± 26.7).

### 3.9.2. Secondary Outcomes {#sec3.9.2}

*Physical Condition Assessed Using the KPS*. Two trials \[[@B18], [@B26]\] reported that moxibustion as a complementary treatment may facilitate improving the physical condition (MD: 6.91, 95% CI: 5.11--8.72, *n* = 128, and *I*^2^ = 0%, low-quality evidence; [Figure 9](#fig9){ref-type="fig"}).

*Quality of Life Assessed Using EORTC QLQ-C30 v3.0*. One trial \[[@B17]\] reported that moxibustion as a complementary treatment may facilitate improving the functional score of patients (32.20 ± 7.74 versus 38.39 ± 7.05). One trial \[[@B30]\] reported that moxibustion may increase the quality of life score (56.93 ± 18.6 versus 63.3 ± 22.1).

### 3.9.3. Adverse Events {#sec3.9.3}

Trials in this group did not report any adverse events in the intervention or control group.

3.10. Effects of Actual Moxibustion versus Placebo Moxibustion {#sec3.10}
--------------------------------------------------------------

One trial \[[@B24]\] reported that actual moxibustion might more effectively reduce the score in the nausea and vomiting domain of EORTC QLQ-C30 v3.0 than placebo moxibustion (8.10 ± 10.98 versus 46.67 ± 23.32). Moxibustion could also improve the quality of life score in EORTC QLQ-C30 v3.0 (77.38 ± 10.62 versus 62.50 ± 23.34) and the KPS (80.86 ± 8.87 versus 70.00 ± 11.70). Moreover, this trial did not report any adverse events in the intervention or control group.

4. Discussion {#sec4}
=============

This systematic review evaluated the effectiveness of moxibustion against CINV. Among trials comparing moxibustion with no treatment, two \[[@B21], [@B28]\] reported that moxibustion might more favorably relieve the severity of CINV. These trials had the following similarities: first, patients were diagnosed as having stage III or IV lung cancer; second, moxibustion was performed at the same acupoints (BL17 and BL19); third, cis-platinum was used as the chemotherapeutic drug. The results suggest that moxibustion at the BL17 and BL19 acupoints can alleviate CINV in patients with lung cancer. Zhong\'s trial \[[@B28]\] was considered as having high reporting bias; this is because although he reported that some patients may have used supportive treatment and ondansetron for severe vomiting, he did not specify who these patients are. A trial \[[@B27]\] that conducted assessments using EORTC QLQ-C30 v3.0 reported that moxibustion might effectively relieve the severity of CINV, but a meta-analysis could not be conducted on a single trial. Moreover, the sample size of this trial was too small to provide strong evidence.

Among the trials comparing actual moxibustion with placebo moxibustion, one \[[@B24]\] showed that actual moxibustion might be more effective than placebo moxibustion in relieving the severity of CINV. Despite no meta-analysis of this trial, the result may still suggest that actual moxibustion has specific effects on CINV. This trial has two sources of bias. First, because patient blinding was not assessed in this trial, it could not estimate whether insulating the heat by using a thick paper successfully blinded the patients. Second, the sample size of this trial was too small to confirm the effectiveness of actual moxibustion. Therefore, the aforementioned suggestion is unreliable.

In conclusion, expectation effects were not determined in trials comparing moxibustion with no treatment and placebo moxibustion. The positive response might be because of the expectation or placebo effects of moxibustion. Thus, because of the low quality of the included trials, we could not obtain robust results on the effectiveness of moxibustion in relieving the severity and frequency of CINV.

Serotonin (5-HT3) receptor antagonists were recommended according to the National Comprehensive Cancer Network guidelines in Oncology-Antiemesis Version 2.2014 \[[@B6]\] and ASCO guideline for antiemetic in oncology update 2006 \[[@B1]\]. According to the ASCO guideline, five 5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, palonosetron, and tropisetron) have equivalent efficacy at the same doses. One meta-analysis \[[@B34]\] revealed no difference among ondansetron, granisetron, and dolasetron mesylate. Among the trials comparing moxibustion with antiemetic drugs, four trials \[[@B19], [@B20], [@B23], [@B25]\] measured the outcomes by using the WHO criterion. The results with acceptable heterogeneity level showed that moxibustion may more favorably relieve the severity of CINV. One trial \[[@B16]\], measuring the outcomes by using the ESMO criterion 1996, reported that moxibustion may be more effective than antiemetic drugs in relieving CINV. In these five RCTs, 5-HT antagonists were used as the antiemetic drugs (ondansetron in three trials \[[@B19], [@B20], [@B23]\], granisetron in one trial \[[@B25]\], and tropisetron in one trial \[[@B16]\]); therefore, the results suggested more favorable effects of moxibustion than of 5-HT receptor antagonists. However, the results are not adequately reliable because of the low quality of the included trials.

Among the studies comparing moxibustion plus antiemetic drugs with antiemetic drugs alone, three RCTs \[[@B18], [@B26], [@B31]\] showed that moxibustion might enhance the effects of antiemetic drugs. Two trials \[[@B22], [@B29]\] measured the outcomes by using the EMSO criterion 1990 with high heterogeneity level revealing that moxibustion could not enhance the effects of antiemetic drugs. The heterogeneity of the two trials may be related to the various types of cancer. The remaining two trials measured outcomes by using EMSO criterion 1996 \[[@B17]\] and EORTC QLQ-C30 v3.0 \[[@B30]\]. These two trials also reported that moxibustion might enhance the effects of antiemetic drugs, but a meta-analysis could not be conducted because these trials had different criteria. The results of these six trials were not consistent; thus we could not obtain robust results on the effectiveness of moxibustion in enhancing the effects of antiemetic drugs as a complementary treatment. Additional trials on CINV are warranted to confirm the results.

For secondary outcomes, among the trials comparing moxibustion with no treatment, three \[[@B21], [@B27], [@B28]\] reported that moxibustion might improve the physical condition of patients, as measured using the KPS. We considered that the heterogeneity was engendered by Zhong\'s trial, because of the supportive treatment or ondansetron. Among the trials comparing actual moxibustion with placebo moxibustion, one \[[@B24]\] reported that moxibustion might be more effective than placebo moxibustion in improving the physical condition and quality of life of patients. However, because of the heterogeneity of these trials, the aforementioned result is not adequately reliable.

In the comparison of moxibustion with antiemetic drugs, two trials \[[@B16], [@B19]\] showed that moxibustion could more effectively improve the physical condition of patients than antiemetic drugs. More relevant trials are warranted to confirm the results because of the low quality and small sample size of the above trials.

Regarding the comparison of moxibustion plus antiemetic drugs with antiemetic drugs alone, two trials revealed that moxibustion, as a complementary treatment, may facilitate improving the physical condition of patients, as measured using the KPS \[[@B18], [@B26]\]. The remaining two trials, measured using EORTC QLQ-C30 v3.0 \[[@B17], [@B30]\], showed that moxibustion, as a complementary treatment, may facilitate improving the physical condition and quality of life of patients. A meta-analysis could not be conducted because these two trials did not apply the same domain of EORTC QLQ-C30 v3.0 criterion.

In conclusion, although the results of the included trials were consistent, the quality of the trials was low. Therefore, the results are not adequately reliable.

Moxibustion may induce few adverse events. Two trials \[[@B21], [@B27]\] reported no adverse events in the intervention or control group. Moreover, other trials did not report any adverse events. Therefore, based on current evidence, moxibustion is a safe treatment.

All the included trials had two sources of bias. First, the included RCTs used a poor methodology and were not registered in the clinical trial registry. Most trials did not mention the procedures of randomization, allocation concealment, and blinding of statisticians. No trial reported the method of sample size calculation. Therefore, the evidence level of this systematic review is low. Second, all trials were published in Chinese, and most trials were conducted in China. Therefore, definite conclusions for other countries and races could not be derived.

This review has some limitations. First, funnel plots could not detect reporting bias because of the limited number of trials. Second, patient blinding method was not rigorous in the included trial. Suitable sham control device is warranted to further trials. A new moxa device for sham treatment developed by Zhao \[[@B35]\] might be a choice. Furthermore, we could not determine expectation effects because no trials assessed the expectation effects of moxibustion. Third, several reasons affected the results, including differences in the type, frequency, acupoints, and course of moxibustion and course of chemotherapy in each trial. Finally, we included RCTs published only in Chinese and English because of language barriers; thus, we may have missed some high-quality trials published in other languages.

5. Conclusion {#sec5}
=============

Moxibustion might effectively relieve the severity and frequency of CINV; however, the expectation effects and the effects of placebo moxibustion cannot be excluded. Moxibustion might be more effective than antiemetic drugs. There is no robust result that moxibustion could enhance the effects of antiemetic drugs as a complementary treatment because of inconsistent results. It might also improve the physical condition and quality of life of patients with cancer. In addition, current evidence reveals that moxibustion is a safe treatment with few adverse events. However, the conclusion of this review is limited because of the lack of high-quality RCTs; further evidence is warranted to update this systematic review.
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![Forest plot of the effects of moxibustion plus antiemetic drugs on relieving the severity of CINV (measured using the WHO criterion) compared with the effects of antiemetic drugs alone.](ECAM2017-9854893.007){#fig7}

![Forest plot of the effects of moxibustion plus antiemetic drugs on relieving the severity and frequency of CINV (measured using the EMSO criterion 1990) compared with the effects of antiemetic drugs alone.](ECAM2017-9854893.008){#fig8}

![Forest plot of the effects of moxibustion plus antiemetic drugs on improving physical condition (measured using the KPS) compared with the effects of antiemetic drugs alone.](ECAM2017-9854893.009){#fig9}

###### 

Characteristics of each trial.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Design             Sample size     Intervention type                Control group                                                                     Moxibustion regimen                                                Outcome measure        Adverse events
  ----------------------- ------------------ --------------- -------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------ ---------------------- ----------------------------------
  Zhong 2014 \[[@B28]\]   Parallel, 2 arms   60 (30/30)      Ginger-partitioned moxibustion   Supportive treatment;\                                                            From 3 days before to 14 days after chemotherapy, qd               WHO;\                  Not reported
                                                                                              ondansetron only in serious vomiting occurs                                                                                                          KPS                    

  Zhang 2008 \[[@B27]\]   Parallel, 3 arms   90 (30/30/30)   Ginger-partitioned moxibustion   No treatment                                                                      During the chemotherapy, qd                                        EORTC QLQ-C30 v3.0;\   No adverse events in both groups
                                                                                                                                                                                                                                                   KPS                    

  Zhang 2016 \[[@B26]\]   Parallel, 2 arms   60 (30/30)      Direct moxibustion               Conventional dosage of ondansetron                                                Once a day for 7 days                                              WHO;\                  Not reported
                                                                                                                                                                                                                                                   KPS                    

  Ruan 2014 \[[@B20]\]    Parallel, 2 arms   91 (45/46)      Herb-partitioned moxibustion     Ondansetron 8 mg, dexamethasone 5 mg, day 1 to day 3, qd\                         Once a day for 14 days                                             WHO                    Not reported
                                                                                              omeprazole 40 mg day 4 to day 7, qd\                                                                                                                                        
                                                                                              metoclopramide 10 mg, tid                                                                                                                                                   

  Zhong 2011 \[[@B25]\]   Parallel, 2 arms   58 (29/29)      Ginger-partitioned moxibustion   Granisetron hydrochloride 3 mg, before and after chemotherapy                     Once a day for 3 days                                              WHO                    Not reported

  Xiang 2011 \[[@B23]\]   Parallel, 2 arms   60 (30/30)      Direct moxibustion               Ondansetron hydrochloride 8 mg, before chemotherapy                               1 day before chemotherapy to 3 days after chemotherapy             WHO                    Not reported

  Wang 2010 \[[@B21]\]    Parallel, 2 arms   60 (30/30)      Direct moxibustion               No treatment                                                                      During the chemotherapy, qd                                        WHO;\                  No adverse events in both groups
                                                                                                                                                                                                                                                   KPS                    

  Zhou 2005 \[[@B22]\]    Parallel, 2 arms   100 (50/50)     Direct moxibustion               Granisetron hydrochloride 30 mg, before chemotherapy                              Twice a day for 7 days                                             ESMO                   Not reported

  Xu 2014 \[[@B24]\]      Parallel, 2 arms   50 (25/25)      Ginger-partitioned moxibustion   Placebo moxibustion                                                               From 5 days before to 60 days after chemotherapy, 3 times a week   EORTC QLQ-C30 v3.0;\   Not reported
                                                                                                                                                                                                                                                   KPS                    

  Liu 2010 \[[@B19]\]     Parallel, 2 arms   62 (32/30)      Direct moxibustion               Conventional dosage of dexamethasone and ondansetron                              Once a day for 7 days                                              WHO;\                  Not reported
                                                                                                                                                                                                                                                   KPS                    

  Liang 2014 \[[@B18]\]   Parallel, 2 arms   68 (34/34)      Ginger-partitioned moxibustion   Ranitidine 150 mg, granisetron 3 mg, and nutritional support                      Once a day for 63 days                                             WHO;\                  Not reported
                                                                                                                                                                                                                                                   KPS                    

  Hao 2014 \[[@B17]\]     Parallel, 2 arms   61 (31/30)      Direct moxibustion               Conventional dosage of dexamethasone, tropisetron, promethazine, and cimetidine   During the chemotherapy, qd                                        ESMO;\                 Not reported
                                                                                                                                                                                                                                                   EORTC QLQ-C30 v3.0     

  Gao 2015 \[[@B16]\]     Parallel, 2 arms   60 (30/30)      Direct moxibustion               Conventional dosage of dexamethasone, tropisetron, and lansoprazole               During the chemotherapy, 6 times a week                            ESMO;\                 Not reported
                                                                                                                                                                                                                                                   KPS                    

  Li 2015 \[[@B29]\]      Parallel, 2 arms   169 (85/84)     Moxa box moxibustion             Tropisetron hydrochloride 5 mg                                                    Twice a day for 8 days                                             ESMO                   Not reported

  Ya 2010 \[[@B30]\]      Parallel, 2 arms   24 (12/12)      Direct moxibustion               Conventional dosage of dexamethasone and ondansetron                              Once a day for 5 days                                              EORTC QLQ-C30 v3.0     Not reported

  Zhang 2016 \[[@B31]\]   Parallel, 2 arms   50 (25/25)      Direct moxibustion               Tropisetron 5 mg before chemotherapy                                              Once a day for 6 days                                              WHO                    Not reported
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Notes*. WHO: WHO criterion for the acute and subacute toxicity of anticancer agents, KPS: Karnofsky performance score, EORTC QLQ-C30 v3.0: the European Organization for Research on Treatment of Cancer\'s questionnaire to assess the quality of life v3.0, and ESMO: the Eastern Society for Medical Oncology criterion.

###### 

Risk of bias for included trials.

  Study                   Sequence generation   Allocation concealment   Blinding   Incomplete outcome data   Selective outcome reporting   Other sources of bias
  ----------------------- --------------------- ------------------------ ---------- ------------------------- ----------------------------- -----------------------
  Zhong 2014 \[[@B28]\]   (−)                   0                        0          (−)                       (+)                           (−)
  Zhang 2008 \[[@B27]\]   (−)                   0                        0          (−)                       (−)                           (−)
  Zhang 2016 \[[@B26]\]   0                     0                        0          (−)                       (−)                           (−)
  Ruan 2014 \[[@B20]\]    (−)                   0                        0          (−)                       (−)                           (−)
  Zhong 2011 \[[@B25]\]   (−)                   0                        0          (−)                       (+)                           (−)
  Xiang 2011 \[[@B23]\]   0                     0                        0          (−)                       (−)                           (−)
  Wang 2010 \[[@B21]\]    (−)                   0                        0          (−)                       (−)                           (−)
  Zhou 2005 \[[@B22]\]    0                     0                        0          (−)                       (−)                           0
  Xu 2014 \[[@B24]\]      (−)                   0                        0          (−)                       (−)                           0
  Liu 2010 \[[@B19]\]     0                     0                        0          (−)                       (−)                           (−)
  Liang 2014 \[[@B18]\]   (−)                   0                        0          (−)                       (−)                           (−)
  Hao 2014 \[[@B17]\]     (−)                   0                        0          (−)                       (−)                           (−)
  Gao 2015 \[[@B16]\]     (−)                   0                        0          (−)                       (−)                           (−)
  Li 2015 \[[@B29]\]      0                     0                        0          (−)                       (−)                           0
  Ya 2010 \[[@B30]\]      0                     0                        0          (−)                       (−)                           (−)
  Zhang 2016 \[[@B31]\]   (−)                   0                        0          (−)                       (−)                           (−)

*Note*. Low risk of bias: (−); unclear: 0; high risk of bias: (+).

[^1]: Academic Editor: Kieran Cooley
